Trubion Pharmaceuticals , Nasdaq: TRBN
Developing novel drugs to treat rheumatoid arthritis and systemic lupus erythematosus.
Industry: Health Care
First Day Return: +0.7%
Industry: Health Care
TRBN
Developing novel drugs to treat rheumatoid arthritis and systemic lupus erythematosus.
| IPO Data | |
|---|---|
| IPO File Date | 06/02/2006 |
| Offer Price | $13.00 |
| Price Range $13.00 - $15.00 | |
| Offer Shares (mm) | 4.0 |
| Deal Size ($mm) | $52 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 10/17/2006 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $52 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Seattle, WA, United States |
| Founded | 1999 |
| Employees at IPO | 72 |
| Website www.trubion.com | |
IPO News for Trubion Pharmaceuticals
Trubion Pharmaceuticals (TRBN) Performance
